Pharming Group Nv · EURONEXT:PHARM
Pharming Group Nv — Q3 2026 Earnings Presentation
32 slides from Pharming Group Nv's earnings presentation, Oct 27, 2026
Slide 1: Third quarter 2026 financial results
OCTOBER 27, 2026 Third quarter 2026 NASDAQ: PHAR financial results EURONEXT Amsterdam: PHARM 1
Slide 2: Introduction
Co-CEO & CFO Kenneth Lynard Interim Co-CEO & Chief Financial Officer Introduction 2
Slide 3: Speakers
Speakers Leverne Marsh Kenneth Lynard Anurag Relan, MD Interim Co-CEO & Interim Co-CEO & Chief Medical Officer Chief Commercial Officer Chief Financial Officer 3
Slide 4: Forward-looking statements
Forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual resu
Slide 5: Strong commercial foundation with high-value pipeline
Strong commercial foundation with high-value pipeline HAE PIDs PMD Hereditary Angioedema Primary Immunodeficiencies Primary Mitochondrial with immune dysregulation Disease RUCONEST® Joenja® (leniolisib) napazimone (KL1333) APPROVED for acute HAE APPROVED for APDS CLINICAL • Cornerstone on-demand • A
Slide 6: Q3 2026 financial and commercial update
Q3 2026 financial and commercial update Revenues RUCONEST stabilization and return to growth RUCONEST Joenja • U.S. demand stabilized with vial volume returning to PY levels 117.6 • 14% revenue growth Amounts in US$ million 97.3 +21% 23.8 15.1 Joenja growth momentum • 58% revenue growth, geographic
Slide 7: Progress on near-term milestones
Progress on near-term milestones RUCONEST for HAE Revenues returned to growth and demand stabilized Geographic expansion – Germany and Japan launches Joenja for APDS Pediatric label expansion (U.S.) Joenja (leniolisib) Positive genetic PIDs Phase II readout (October) for additional PIDs Phase II tri
Slide 8: Commercial update
Co-CEO & CCO Leverne Marsh Interim Co-CEO & Chief Commercial Officer Commercial update 8
Slide 9: RUCONEST Q3 update – returned to revenue growth
RUCONEST Q3 update – returned to revenue growth RUCONEST revenue RUCONEST quarterly revenue (global) (global) 93.8 Revenue +14% vs. Q3 2025 93.8 82.2 80.4 US demand returned to PY level 72.3 Amounts in US$ million 68.6 in volume terms Amounts in US$ million 82.2 +14% 58.4 Early seasonal inventory in
Slide 10: RUCONEST – resilient market position in high-burden HAE
RUCONEST – resilient market position in high-burden HAE Differentiated value proposition Overwhelming majority of • Targets the root cause of HAE across all pathways • Median time to complete attack resolution of 4.5hrs RUCONEST patients remain on therapy one year into oral competitor launch Mostly
Slide 11: Joenja Q3 update – strong global momentum in APDS
Joenja Q3 update – strong global momentum in APDS Continued U.S. growth and international launches Joenja revenue (global) U.S. patients on Joenja Revenue +58% U.S. EU & RoW 136 132 127 136 patients on therapy in US 120 (+17% vs 3Q25) 23.8 114 116 Amounts in US$ million 7.9 102 Significant increase
Slide 12: Joenja for APDS – pediatric label expansion
Joenja for APDS – pediatric label expansion U.S. FDA approval received September 11, 2026 >60 Eligible patients (ages 4–11) identified in the U.S. APPROVED UNDER FDA REVIEW Children aged 4 to 11, at least 27 kg Children aged 4 to 11, 13 kg to less than 27 kg • sNDA approved – September 11, 2026 • Se
Slide 13: Joenja expansion from APDS foundation into broad immunology opportunity
Joenja expansion from APDS foundation into broad blockbuster immunology opportunity Broad PIDs/CVID Opportunity*** International APDS Expansion • Genetic PIDs with U.S. APDS immune dysregulation Expansion • Focused geo- (>2,500 U.S. patients) Established APDS expansion that Commercial Base • Pediatr
Slide 14: R&D update
CMO Anurag Relan Chief Medical Officer R&D update 14
Slide 15: Leniolisib opportunity: shared PI3Kδ-driven immune dysregulation across PIDs
Leniolisib opportunity: Targeting shared PI3Kδ-driven immune dysregulation across primary immunodeficiencies (PIDs) E X P A N D I N G T H E A D D R E S S A BL E M A R K E T ONE MECHANISM: PI3Kδ Shared clinical manifestations across all three populations Up to 26× the APDS Genetic PIDs + CVID populat
Slide 16: Leniolisib Phase II trials in genetic PIDs and CVID
Leniolisib Phase II trials in genetic PIDs and CVID Positive data presented at ESID 2026 N = 13 Topline results expected November N = 20 Genetic PIDs with immune dysregulation CVID with immune dysregulation Open-label, single-arm basket trial at NIH Open-label, single-arm, multi-center dose-confirma
Slide 17: Genetic PIDs study: leniolisib well-tolerated, improved immune dysregulation measures
Genetic PIDs study: leniolisib was well-tolerated and improved multiple measures of immune dysregulation First clinical data for leniolisib in a larger group of PID participants beyond APDS Improvement across objective and clinician-reported measures, consistent with PI3Kδ mechanism LUNG FUNCTION –
Slide 18: Leniolisib Phase II trials – CVID results expected in November
Leniolisib Phase II trials – CVID results expected in November Positive data presented at ESID 2026 N = 13 Topline results expected November N = 20 Genetic PIDs with immune dysregulation CVID with immune dysregulation Open-label, single-arm basket trial at NIH Open-label, single-arm, multi-center do
Slide 19: Napazimone (KL1333) for mtDNA-driven primary mitochondrial disease
Napazimone (KL1333) for mtDNA-driven primary mitochondrial disease Aiming for the first disease-modifying treatment DYSFUNCTIONAL MITOCHONDRIA Targets the underlying pathology Normalizes the NAD+/NADH ratio and mitochondrial function, with evidence Impaired ETC protein from in vitro data, animal mod
Slide 20: Financial results and outlook
Co-CEO & CFO Kenneth Lynard Interim Co-CEO & Chief Financial Officer Financial results and outlook 20
Slide 21: Financial highlights: Q3 2026 vs Q3 2025
Financial highlights: Q3 2026 vs Q3 2025 Revenues Adjusted (Non-GAAP) Cash flow from operations RUCONEST Joenja Operating profit* 117.6 Amounts in US$ million Amounts in US$ million Amounts in US$ million 97.3 35.0 23.8 32.0 32.4 15.1 +21% 16.0 93.8 82.2 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 20
Slide 22: Financial highlights: 9M 2026 vs 9M 2025
Financial highlights: 9M 2026 vs 9M 2025 Revenues Adjusted (Non-GAAP) Cash flow from operations RUCONEST Joenja Operating profit* 280.2 Amounts in US$ million Amounts in US$ million Amounts in US$ million 269.6 44.0 38.4 55.7 38.0 +4% 29.7 24.7 231.2 224.5 9M 2025 9M 2026 9M 2025 9M 2026 9M 2025 9M
Slide 23: 2026 financial guidance and long-term capital outlook
2026 financial guidance and long-term capital outlook Revenue and operating expenses (in constant currency): FY 2026 Guidance Notes • 1 - 4% growth Total Revenues US$380 - 390 million • COGS: ~11% • 0 - 1% growth Operating Expenses US$310 - 315 million • +US$35 million R&D to advance pipeline Signif
Slide 24: Advancing Pharming as a leading global rare disease company
Advancing Pharming as a leading global rare disease company Strong commercial Significant growth Building a leading rare foundation opportunities disease company Joenja - commercial RUCONEST • Geographic, pediatric and • Disciplined operating model prevalence expansion • Durable cash engine • Scalab
Slide 25: Q&A
Q&A Leverne Marsh Kenneth Lynard Anurag Relan, MD Interim Co-CEO & Interim Co-CEO & Chief Medical Officer Chief Commercial Officer Chief Financial Officer 25
Slide 26: Thank you!
WWW.PHARMING.COM The Netherlands Pharming Group Thank you! Vondellaan 47 2332 AA Leiden The Netherlands United States Pharming Healthcare, Inc. 10 Independence Blvd Suite 401, Joenja® and RUCONEST® are registered trademarks owned by or licensed to Pharming Group N.V. Warren or its affiliates. Other
Slide 27: Appendix
27 Appendix @ Pharming’
Slide 28: Statement of profit and loss
Statement of profit and loss 28
Slide 29: Balance sheet – assets
Balance sheet -— assets Non-current assets Intangible assets Property, plant and equipment Right-of-use assets Long-term prepayments Deferred tax assets Investment accounted for using the equity method Investment in debt instruments designated as at FVTPL Restricted cash Total non-current assets Cur
Slide 30: Balance sheet – liabilities
Balance sheet – liabilities 30
Slide 31: Cash flow (1/2)
Cash flow (1/2) 1 Comparative presentation updated for consistency. 31
Slide 32: Cash flow (2/2)
Cash flow (2/2) 2 Money market funds are classified as cash equivalents from April 1, 2026 32